Company intelligence / Profile preview

CureZome

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

CureZome is a South Korean biotechnology company specializing in the development of exosome-based therapeutics and drug delivery systems. The company leverages its proprietary platform to isolate and engineer exosomes for the treatment of various conditions, including liver diseases, inflammatory disorders, and oncology. By utilizing the natural communication and transport capabilities of extracellular vesicles, CureZome aims to deliver therapeutic payloads with high specificity and reduced immunogenicity. The company's pipeline is currently in the pre-clinical stage, focusing on optimizing exosome cargo and targeting mechanisms.

Therapeutic areas: OncologyImmunologyGastroenterology
Modalities: Exosome-based therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

CZ-PS

Preclinical

Beyond the preview

Go deeper on CureZome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CureZome.

Explore the full profile